Alnylam makes case for lumasiran in infants ahead of FDA ruling

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 11:02 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.

    article source